PMID- 9610907
OWN - NLM
STAT- MEDLINE
DCOM- 19980717
LR  - 20210102
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 21
IP  - 3
DP  - 1998 May
TI  - The use of a cationic liposome formulation (DOTAP) mixed with a recombinant 
      tumor-associated antigen to induce immune responses and protective immunity in 
      mice.
PG  - 159-69
AB  - The cationic liposome DOTAP is a well-known transfection reagent. It has been 
      manufactured and approved for clinical use, is readily available, and can be 
      easily used as an adjuvant. These characteristics prompted us to investigate the 
      effectiveness of DOTAP as an adjuvant to induce immune responses and protective 
      immunity in mice using baculovirus-derived carcinoembryonic antigen (bV-CEA) as a 
      model antigen. Two routes of administration and a dose-response study of bV-CEA 
      were used in BALB/c mice to define the magnitude of the immune response as well 
      as the most effective route of immunization. The results demonstrate differences 
      in antibody titers, immunoglobulin (Ig)G isotype, and T-cell responses between 
      the intravenous (i.v.) or subcutaneous (s.c.) route of immunization. The titer of 
      the anti-CEA antibodies induced by the s.c. immunization was greater than the 
      response by i.v. immunization. The s.c. route enhanced the IgG2a/2b isotype, 
      whereas i.v. immunization elicited primarily IgG1. T-cell proliferation responses 
      and cytokine production paralleled the humoral response (i.e., production was 
      higher in the s.c. immunized animals). No differences in immunological responses 
      were seen using either 25 or 10 microg of bV-CEA three times. An amount of 25 
      microg of bV-CEA/DOTAP given by s.c. immunization was sufficient in protecting 
      mice from the transplant of syngeneic tumor cells transduced with the human CEA 
      gene. We conclude that the cationic liposome DOTAP may be a useful immunoadjuvant 
      for active anti-tumor immunotherapy in future clinical trials. This study will 
      help to define the most effective way to use such an adjuvant.
FAU - Bei, R
AU  - Bei R
AD  - Laboratory of Tumor Immunology and Biology, National Cancer Institute, National 
      Institutes of Health, Bethesda, Maryland, USA.
FAU - Guptill, V
AU  - Guptill V
FAU - Masuelli, L
AU  - Masuelli L
FAU - Kashmiri, S V
AU  - Kashmiri SV
FAU - Muraro, R
AU  - Muraro R
FAU - Frati, L
AU  - Frati L
FAU - Schlom, J
AU  - Schlom J
FAU - Kantor, J
AU  - Kantor J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Quaternary Ammonium Compounds)
RN  - 0 (Recombinant Proteins)
RN  - MR86K0XRQP (1,2-dioleoyloxy-3-(trimethylammonium)propane)
SB  - IM
MH  - Animals
MH  - Antigens/*immunology
MH  - Baculoviridae/genetics
MH  - Carcinoembryonic Antigen/genetics/*immunology
MH  - Cell Line
MH  - Fatty Acids, Monounsaturated/*immunology
MH  - Fluorescent Dyes
MH  - Humans
MH  - Immunization
MH  - Immunoglobulin G/blood
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Neoplasms, Experimental/prevention & control
MH  - Quaternary Ammonium Compounds/*immunology
MH  - Recombinant Proteins
EDAT- 1998/06/04 00:00
MHDA- 1998/06/04 00:01
CRDT- 1998/06/04 00:00
PHST- 1998/06/04 00:00 [pubmed]
PHST- 1998/06/04 00:01 [medline]
PHST- 1998/06/04 00:00 [entrez]
AID - 10.1097/00002371-199805000-00001 [doi]
PST - ppublish
SO  - J Immunother. 1998 May;21(3):159-69. doi: 10.1097/00002371-199805000-00001.